Literature DB >> 21303629

No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients.

Sarah E Siegelaar1, Temo Barwari, Wim Kulik, Joost B Hoekstra, J Hans DeVries.   

Abstract

BACKGROUND: A strong relationship between glycemic variability and oxidative stress in poorly regulated type 2 diabetes (T2DM) on oral medication has been reported. However, this relationship was not seen in type 1 diabetes. The purpose of this study is to reexamine the relation between glycemic variability and oxidative stress in a cohort of T2DM patients on oral medication.
METHODS: Twenty-four patients with T2DM on oral glucose lowering treatment underwent 48 hours of continuous glucose monitoring (CGMS® System GoldTM, Medtronic MiniMed) and simultaneous collection of two consecutive 24-hour urine samples for determination of 15(S)-8-iso-prostaglandin F2α (PGF2α) using high-performance liquid chromatography tandem mass spectrometry. Standard deviation (SD) and mean amplitude of glycemic excursions (MAGE) were calculated as markers of glycemic variability.
RESULTS: Included in the study were 66.7% males with a mean age (range) of 59 (36-76) years and a mean (SD) HbA1c of 6.9% (0.7). Median [interquartile range (IQR)] urinary 15(S)-8-iso-PGF2α excretion was 176.1 (113.6-235.8) pg/mg creatinine. Median (IQR) SD was 31 (23-40) mg/dl and MAGE 85 (56-106) mg/dl. Spearman correlation did not show a significant relation for SD (ρ = 0.15, p = .49) or MAGE (ρ = 0.23, p = .29) with 15(S)-8-iso-PGF2α excretion. Multivariate regression analysis adjusted for age, sex, HbA1c, and exercise did not alter this observation.
CONCLUSIONS: We did not find a relevant relationship between glucose variability and 15(S)-8-iso-PGF2α excretions in T2DM patients well-regulated with oral medication that would support an interaction between hyperglycemia and glucose variability with respect to the formation of reactive oxygen species.
© 2010 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21303629      PMCID: PMC3045241          DOI: 10.1177/193229681100500112

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  20 in total

1.  Biochemistry and molecular cell biology of diabetic complications.

Authors:  M Brownlee
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

2.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Authors:  I M Stratton; A I Adler; H A Neil; D R Matthews; S E Manley; C A Cull; D Hadden; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

3.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

4.  Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial.

Authors:  Curt L Rohlfing; Hsiao-Mei Wiedmeyer; Randie R Little; Jack D England; Alethea Tennill; David E Goldstein
Journal:  Diabetes Care       Date:  2002-02       Impact factor: 19.112

5.  Mean amplitude of glycemic excursions, a measure of diabetic instability.

Authors:  F J Service; G D Molnar; J W Rosevear; E Ackerman; L C Gatewood; W F Taylor
Journal:  Diabetes       Date:  1970-09       Impact factor: 9.461

Review 6.  Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo.

Authors:  L J Roberts; J D Morrow
Journal:  Free Radic Biol Med       Date:  2000-02-15       Impact factor: 7.376

7.  A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism.

Authors:  J D Morrow; K E Hill; R F Burk; T M Nammour; K F Badr; L J Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

8.  Meal-generated oxidative stress in type 2 diabetic patients.

Authors:  A Ceriello; N Bortolotti; E Motz; A Crescentini; S Lizzio; A Russo; L Tonutti; C Taboga
Journal:  Diabetes Care       Date:  1998-09       Impact factor: 19.112

9.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

10.  The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial.

Authors: 
Journal:  Diabetes       Date:  1995-08       Impact factor: 9.461

View more
  16 in total

1.  The need for identifying standardized indices for measuring glucose variability.

Authors:  Fabiana Picconi; Alessandra Di Flaviani; Ilaria Malandrucco; Ilaria Giordani; Susanna Longo; Simona Frontoni
Journal:  J Diabetes Sci Technol       Date:  2012-01-01

2.  8-iso-prostaglandin-F2α: a possible trigger or accelerator of diabetic retinopathy.

Authors:  Ying Zhang; Yi Du; Jian-Feng He; Kai-Jun Li
Journal:  Int J Ophthalmol       Date:  2016-01-18       Impact factor: 1.779

3.  Consensus report: the current role of self-monitoring of blood glucose in non-insulin-treated type 2 diabetes.

Authors:  David C Klonoff; Lawrence Blonde; George Cembrowski; Antonio Roberto Chacra; Guillaume Charpentier; Stephen Colagiuri; George Dailey; Robert A Gabbay; Lutz Heinemann; David Kerr; Antonio Nicolucci; William Polonsky; Oliver Schnell; Robert Vigersky; Jean-François Yale
Journal:  J Diabetes Sci Technol       Date:  2011-11-01

4.  Glucose Variability: Comparison of Different Indices During Continuous Glucose Monitoring in Diabetic Patients.

Authors:  Jean-Pierre Le Floch; Laurence Kessler
Journal:  J Diabetes Sci Technol       Date:  2016-06-28

Review 5.  Clinical Implications of Glucose Variability: Chronic Complications of Diabetes.

Authors:  Hye Seung Jung
Journal:  Endocrinol Metab (Seoul)       Date:  2015-06

6.  Glycemic variability: both sides of the story.

Authors:  Antonio Ceriello; Eric S Kilpatrick
Journal:  Diabetes Care       Date:  2013-08       Impact factor: 19.112

7.  Glucose variability: where it is important and how to measure it.

Authors:  J Hans DeVries
Journal:  Diabetes       Date:  2013-05       Impact factor: 9.461

8.  The effect of high-dose insulin analog initiation therapy on lipid peroxidation products and oxidative stress markers in type 2 diabetic patients.

Authors:  Hazal Tuzcu; Ibrahim Aslan; Mutay Aslan
Journal:  Oxid Med Cell Longev       Date:  2013-03-17       Impact factor: 6.543

9.  Impact of glucose excursion and mean glucose concentration in oral glucose-tolerance test on oxidative stress among Japanese Americans.

Authors:  Shuhei Nakanishi; Masayasu Yoneda; Shusaku Maeda
Journal:  Diabetes Metab Syndr Obes       Date:  2013-11-22       Impact factor: 3.168

Review 10.  Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease?

Authors:  Yoshifumi Saisho
Journal:  Int J Mol Sci       Date:  2014-10-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.